X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
Lead Product(s): Diclofenac
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Benuvia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 27, 2024
Details:
Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.
Lead Product(s): CC8464
Therapeutic Area: Ophthalmology Product Name: CC8464
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2024
Details:
Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.
Lead Product(s): CC8464
Therapeutic Area: Ophthalmology Product Name: CC8464
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2024
Details:
The net proceeds will be used to fund company's continued research and product development of CC8464, an oral, potent, highly selective, peripherally-restricted inhibitor for the treatment of Erythromelalgia.
Lead Product(s): CC8464
Therapeutic Area: Neurology Product Name: CC8464
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 02, 2023
Details:
Chromovert has been successfully used to identify a novel, non-addictive pain blocker that is in clinical development. The company is now making its technology available to the scientific community.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
